MAINE MEDICAL CENTER
- Type
- Teaching hospital
- Where
- Portland, ME
- Medicare CCN
- 200009
- Received
- $1,530,158 in 234 records, 2020 ($81,650 general, $1,448,507 research)
- Source
- CMS Open Payments search ↗
On this site
- Nonprofit contractor: Maine Medical Center Fuzzy (name and state)
- Lobbying client: MAINE MEDICAL CENTER Fuzzy (name and state)
- Patent assignee: Maine Medical Center Fuzzy (name and state)
- Trademark owner: Maine Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2020 | General payment | 44 | $81,650 |
| 2020 | Research payment | 190 | $1,448,507 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 190 | $1,448,507 |
| Grant | 1 | $35,000 |
| Gift | 5 | $31,514 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 18 | $10,796 |
| Education | 8 | $2,253 |
| Royalty or License | 9 | $1,423 |
| Space rental or facility fees (teaching hospital only) | 1 | $500 |
| Charitable Contribution | 2 | $162 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2020-12-31 | Monteris Medical Corporation | $35,000 | Grant | In-kind items and services | Neuroblate Device, Neuroblate | 2020 | |
| 2020-12-31 | Stryker Corporation | $2,762 | Gift | In-kind items and services | SURG - CORE CONSOLE Device, SURGICAL | 2020 | |
| 2020-12-31 | Stryker Corporation | $1,466 | Gift | Cash or cash equivalent | NONE Device, NONE | 2020 | |
| 2020-12-31 | AstraZeneca Pharmaceuticals LP | $693 | Research payment | In-kind items and services | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2020 | |
| 2020-12-31 | Masimo Corporation | $402 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Siemens Medical Solutions USA, Inc. | $116 | Charitable Contribution | In-kind items and services | 2020 | ||
| 2020-12-31 | Masimo Corporation | $89 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2020 | |
| 2020-12-31 | Zimmer Biomet Holdings, Inc. | $2 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, Medical Device | 2020 | |
| 2020-12-28 | Clovis Oncology, Inc. | $7,233 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-12-23 | Stryker Corporation | $899 | Research payment | Cash or cash equivalent | SURPASS Device, FLOW DIVERTER | EVOLVE | 2020 |
| 2020-12-21 | Artivion, Inc. | $923 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | ON-X Prosthetic Heart Valve-Anatomic Suture Ring Postmarket Registry | 2020 |
| 2020-12-17 | AstraZeneca Pharmaceuticals LP | $7,708 | Research payment | Cash or cash equivalent | A Phase III Randomized Double-blind Placebo-controlled Multicenter Study in Adults to Determine the Safety Efficacy and | 2020 | |
| 2020-12-17 | Stryker Corporation | $1,589 | Research payment | Cash or cash equivalent | SURPASS Device, FLOW DIVERTER | EVOLVE | 2020 |
| 2020-12-17 | Stryker Corporation | $606 | Research payment | Cash or cash equivalent | SURPASS Device, FLOW DIVERTER | EVOLVE | 2020 |
| 2020-12-15 | GlaxoSmithKline, LLC. | $12,758 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-12-15 | Janssen Research & Development, LLC | $2,154 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2020 | |
| 2020-12-14 | Medical Device Business Services, Inc. | $324 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2020 |
| 2020-12-10 | Aesculap, Inc. | $1,134 | Gift | Cash or cash equivalent | 2020 | ||
| 2020-12-10 | Agios Pharmaceuticals, Inc. | $1,108 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, No | 2020 | |
| 2020-12-02 | ABBVIE INC. | $958 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-12-01 | GlaxoSmithKline, LLC. | $6,416 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2020 | |
| 2020-12-01 | Kowa Research Institute, Inc. | $2,691 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-11-24 | GlaxoSmithKline, LLC. | $21,529 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-11-24 | SK Life Science, Inc. | $5,098 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 059566 | 2020 |
| 2020-11-24 | H. Lundbeck A S | $1,200 | Research payment | Cash or cash equivalent | NORTHERA Drug, NEUROLOGY | A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidop | 2020 |
| 2020-11-23 | Janssen Research & Development, LLC | $5,582 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2020 | |
| 2020-11-21 | Amgen Inc. | $8,162 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2020 |
| 2020-11-16 | Janssen Research & Development, LLC | $503 | Research payment | Cash or cash equivalent | A multi center prospective long term observational registry of pediatric patients with IBS | 2020 | |
| 2020-11-10 | SANOFI PASTEUR INC. | $8,855 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-11-09 | Amgen Inc. | $6,750 | Research payment | In-kind items and services | Repatha Biological, Cardiology | A randomized trial of evolocumab on saphenous vein graft patency following coronary artery bypass surgery (NEWTON-CABG) | 2020 |
| 2020-11-09 | GENZYME CORPORATION | $625 | Research payment | Cash or cash equivalent | Fabry LSD Data Registry | 2020 | |
| 2020-11-09 | GENZYME CORPORATION | $150 | Research payment | Cash or cash equivalent | Gaucher LSD Data Registry | 2020 | |
| 2020-11-03 | Artivion, Inc. | $1,625 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | ON-X Prosthetic Heart Valve-Anatomic Suture Ring Postmarket Registry | 2020 |
| 2020-11-03 | Kowa Research Institute, Inc. | $1,170 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-10-29 | Clovis Oncology, Inc. | $7,147 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-10-29 | Cardiovascular Systems Inc. | $39 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-10-27 | CSL Behring | $308 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-10-27 | CSL Behring | $152 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-10-26 | Genentech, Inc. | $25,151 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-10-26 | Janssen Research & Development, LLC | $9,262 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2020 | |
| 2020-10-26 | Genentech, Inc. | $4,205 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-10-23 | Amgen Inc. | $1,290 | Research payment | In-kind items and services | Repatha Biological, Cardiology | VESALIUS - CV | 2020 |
| 2020-10-21 | Artivion, Inc. | $12,580 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | ON-X Prosthetic Heart Valve-Anatomic Suture Ring Postmarket Registry | 2020 |
| 2020-10-20 | GlaxoSmithKline, LLC. | $12,047 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-10-19 | SK Life Science, Inc. | $3,470 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-10-19 | FUJIFILM SonoSite, Inc. | $406 | Education | In-kind items and services | Edge/Edge II Ultrasound System Device, Medical Device | 2020 | |
| 2020-10-13 | Stryker Corporation | $1,942 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $951 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $141 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-13 | Stryker Corporation | $51 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-10-12 | Medical Device Business Services, Inc. | $5,496 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2020 |
| 2020-10-06 | GlaxoSmithKline, LLC. | $3,199 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-10-05 | PFIZER INC. | $12,750 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2020 |
| 2020-10-01 | Abbott Laboratories | $800 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | 2020 |
| 2020-09-28 | Genentech, Inc. | $2,585 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-09-24 | Kowa Research Institute, Inc. | $3,159 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-09-21 | Gilead Sciences, Inc. | $1,627 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-09-21 | Gilead Sciences, Inc. | $1,627 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-09-17 | Abbott Laboratories | $800 | Research payment | Cash or cash equivalent | ABSORB Device, Vascular | ABSORB III Randomized Controlled Trial (RCT) (ABSORB-III) | 2020 |
| 2020-09-17 | Edwards Lifesciences Corporation | $149 | Research payment | Cash or cash equivalent | Early-TAVR Trial #2016-07 | 2020 | |
| 2020-09-16 | ABBVIE INC. | $702 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-09-15 | GlaxoSmithKline, LLC. | $20,552 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-09-15 | VERTEX PHARMACEUTICALS INCORPORATED | $3,500 | Research payment | Cash or cash equivalent | An Observational Study to Evaluate the Real-world Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor on the Burden of Ill | 2020 | |
| 2020-09-11 | Janssen Research & Development, LLC | $11,082 | Research payment | Cash or cash equivalent | A multi center prospective long term observational registry of pediatric patients with IBS | 2020 | |
| 2020-09-08 | Medtronic USA, Inc. | $35,000 | Research payment | In-kind items and services | INTELLIS Device, Spinal Cord Neurostimulation | Investigator Sponsored Research | 2020 |
| 2020-09-08 | Incyte Corporation | $74 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $69 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $63 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $40 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $37 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $37 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $32 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $30 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $21 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $19 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $6 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $3 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $3 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Pilot Study of the Immunological Effects of Neo Adjuvant INCB024360 in Patients with Epithelial Ovarian, Fallopian Tub | 2020 | |
| 2020-09-04 | Olympus America Inc. | $418 | Education | In-kind items and services | CDS Other Device, Medical | 2020 | |
| 2020-09-03 | SK Life Science, Inc. | $1,242 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 59566 | 2020 |
| 2020-08-27 | Genentech, Inc. | $7,569 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-08-27 | Stryker Corporation | $5,000 | Research payment | Cash or cash equivalent | SURPASS Device, FLOW DIVERTER | EVOLVE | 2020 |
| 2020-08-26 | Kowa Research Institute, Inc. | $585 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-08-21 | GENZYME CORPORATION | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | THYMOGLOBULIN Biological, Oncology | 2020 | |
| 2020-08-18 | GlaxoSmithKline, LLC. | $10,917 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-08-18 | Eli Lilly and Company | $626 | Research payment | In-kind items and services | ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | 2020 | |
| 2020-08-17 | Medtronic Vascular, Inc. | $2,482 | Research payment | Cash or cash equivalent | Endurant EVO US | 2020 | |
| 2020-08-11 | SK Life Science, Inc. | $796 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 59566 | 2020 |
| 2020-08-11 | CSL Behring | $267 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-08-10 | Clovis Oncology, Inc. | $7,737 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-08-06 | GlaxoSmithKline, LLC. | $1,950 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2020 | |
| 2020-08-06 | ABBVIE INC. | $1,304 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | P12-792 | 2020 |
| 2020-08-06 | VIVUS LLC | $438 | Research payment | Cash or cash equivalent | PANCREAZE Drug, CYSTIC FIBROSIS | Long-term Study in US Cystic Fibrosis | 2020 |
| 2020-08-03 | Genentech, Inc. | $10,443 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-07-28 | CSL Behring | $374 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-07-27 | Kowa Research Institute, Inc. | $2,691 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $12,159 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-07-22 | Gilead Sciences, Inc. | $430 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-07-21 | GlaxoSmithKline, LLC. | $17,346 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-07-21 | SK Life Science, Inc. | $3,951 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 59566 | 2020 |
| 2020-07-20 | SK Life Science, Inc. | $2,417 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-07-16 | Bard Peripheral Vascular, Inc. | $1,882 | Research payment | Cash or cash equivalent | LUTONIX Device, BD Interventional - Peripheral Intervention | SAFE-DCB Registry BPV14006 | 2020 |
| 2020-07-13 | AKEBIA THERAPEUTICS INC | $1,737 | Research payment | Cash or cash equivalent | PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF ORAL VADADUSTAT FOR THE C | 2020 | |
| 2020-07-09 | CSL Behring | $127 | Research payment | In-kind items and services | A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody | 2020 | |
| 2020-07-09 | Amgen Inc. | $34 | Research payment | In-kind items and services | GALACTIC - HF | 2020 | |
| 2020-07-07 | GlaxoSmithKline, LLC. | $9,991 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-07-07 | Medical Device Business Services, Inc. | $1,464 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2020 |
| 2020-07-06 | Stryker Corporation | $1,293 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $480 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $53 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-06 | Stryker Corporation | $17 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-07-02 | GlaxoSmithKline, LLC. | $565 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2020 | |
| 2020-06-30 | GE HEALTHCARE | $46 | Charitable Contribution | Cash or cash equivalent | 2020 | ||
| 2020-06-25 | Janssen Research & Development, LLC | $13,370 | Research payment | Cash or cash equivalent | A multi center prospective long term observational registry of pediatric patients with IBS | 2020 | |
| 2020-06-25 | Janssen Research & Development, LLC | $1,832 | Research payment | Cash or cash equivalent | A Phase 2 Study of Erdafitinib in Subjects with Advanced Solid Tumors and FGFR Gene Alterations | 2020 | |
| 2020-06-24 | Kowa Research Institute, Inc. | $1,638 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-06-23 | Agios Pharmaceuticals, Inc. | $10,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, No | 2020 | |
| 2020-06-22 | SK Life Science, Inc. | $3,220 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C025 | 2020 |
| 2020-06-22 | SK Life Science, Inc. | $1,215 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-06-20 | Amgen Inc. | $7,620 | Research payment | Cash or cash equivalent | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $86,239 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-06-17 | Gilead Sciences, Inc. | $24,574 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-06-16 | GlaxoSmithKline, LLC. | $2,155 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2020 | |
| 2020-06-16 | GlaxoSmithKline, LLC. | $1,950 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2020 | |
| 2020-06-16 | Genentech, Inc. | $165 | Research payment | Cash or cash equivalent | Non-Covered Product Drug, None | PRODROMAL TO MILD AD | 2020 |
| 2020-06-15 | SK Life Science, Inc. | $3,585 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-06-08 | Clovis Oncology, Inc. | $15,271 | Research payment | Cash or cash equivalent | Rubraca Drug, ONCOLOGY | A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Fro | 2020 |
| 2020-06-04 | SANOFI PASTEUR INC. | $22,885 | Research payment | Cash or cash equivalent | STA00011 Stamaril Yellow Fever | 2020 | |
| 2020-05-27 | GlaxoSmithKline, LLC. | $4,492 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-05-22 | Kowa Research Institute, Inc. | $585 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $93,207 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-05-20 | Genentech, Inc. | $29,087 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-05-20 | Gilead Sciences, Inc. | $11,352 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-05-20 | Kowa Research Institute, Inc. | $2,223 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-05-19 | GlaxoSmithKline, LLC. | $40,313 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2020 | |
| 2020-05-19 | GlaxoSmithKline, LLC. | $22,014 | Research payment | Cash or cash equivalent | A PHASE 1 DOSE ESCALATION AND COHORT EXPANSION STUDY OF TSR-042, AN AN | 2020 | |
| 2020-05-18 | Genentech, Inc. | $650 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-05-14 | CSL Behring | $764 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-05-12 | SK Life Science, Inc. | $1,668 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-05-06 | LivaNova USA, Inc. | $2,508 | Research payment | Cash or cash equivalent | Perceval Device, Cardiology/Vascular Diseases | Behavior of Valve Leaflets and the Incidence of Reduced Mobility Post-Surgical Aortic Valve Implant | 2020 |
| 2020-05-06 | LivaNova USA, Inc. | $888 | Research payment | Cash or cash equivalent | Perceval Device, Cardiology/Vascular Diseases | Sorin Universal Registry on Aortic Valve Replacement | 2020 |
| 2020-05-04 | Genentech, Inc. | $30,754 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-05-04 | Genentech, Inc. | $18,330 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-05-01 | SK Life Science, Inc. | $2,206 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | 1-FA7759 | 2020 |
| 2020-05-01 | Stryker Corporation | $1,667 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $783 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $156 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-05-01 | Stryker Corporation | $40 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2020 | |
| 2020-04-30 | Cardiovascular Systems Inc. | $4,116 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-04-28 | GlaxoSmithKline, LLC. | $25,952 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-04-28 | GlaxoSmithKline, LLC. | $10,505 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-04-27 | Gilead Sciences, Inc. | $24,681 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-04-27 | EMD Serono, Inc. | $9,765 | Research payment | Cash or cash equivalent | Bavencio Drug, Oncology | Study of Avelumab + M6620 + Carboplatin in Poly (Adenosine diphosphate ribose [ADP]-ribose) polymerase inhibitor (PARPi) | 2020 |
| 2020-04-27 | SK Life Science, Inc. | $7,251 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C033 | 2020 |
| 2020-04-27 | CSL Behring | $82 | Research payment | In-kind items and services | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-04-26 | Artivion, Inc. | $1,450 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | ON-X Prosthetic Heart Valve-Anatomic Suture Ring Postmarket Registry | 2020 |
| 2020-04-23 | Medical Device Business Services, Inc. | $3,000 | Research payment | Cash or cash equivalent | MICRUSFRAME Device, Neurovascular | A Prospective multi center single arm study to obtain real world clinical data and characterize the acute and long term | 2020 |
| 2020-04-22 | ABBVIE INC. | $2,761 | Research payment | Cash or cash equivalent | HUMIRA Biological, IMMUNOLOGY | P11-292 | 2020 |
| 2020-04-20 | Gilead Sciences, Inc. | $12,161 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study in Coronavirus, Severe Subjects | 2020 |
| 2020-04-20 | Gilead Sciences, Inc. | $12,161 | Research payment | Cash or cash equivalent | Veklury Drug, COVID-19 | The Simple Study - Subjects with Mild to Moderate Coronavirus Infection | 2020 |
| 2020-04-13 | Amgen Inc. | $16,556 | Research payment | In-kind items and services | Repatha Biological, Cardiology | FOURIER OLE (Ph 4) | 2020 |
| 2020-04-08 | E.R. Squibb & Sons, L.L.C. | $17,842 | Research payment | Cash or cash equivalent | Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix (Belatac | 2020 | |
| 2020-04-06 | GlaxoSmithKline, LLC. | $25,203 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PHASE 3 COMPARISON OF PLATINUM-BASED THERA | 2020 | |
| 2020-04-02 | Cardiovascular Systems Inc. | $75 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-04-01 | Kowa Research Institute, Inc. | $7,488 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-03-31 | AstraZeneca Pharmaceuticals LP | $11,526 | Research payment | Cash or cash equivalent | IMFINZI Drug, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2020 |
| 2020-03-23 | Janssen Research & Development, LLC | $15,598 | Research payment | Cash or cash equivalent | A multi center prospective long term observational registry of pediatric patients with IBS | 2020 | |
| 2020-03-10 | SK Life Science, Inc. | $1,600 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial O | 2020 |
| 2020-03-10 | SK Life Science, Inc. | $34 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial O | 2020 |
| 2020-03-05 | Draeger Medical Systems, Inc | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2020 | ||
| 2020-03-05 | Cardiovascular Systems Inc. | $62 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-03-03 | Genentech, Inc. | $163,501 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | A PHASE III MULTICENTER RANDOMIZED PLACEBO CONTROLLED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO IN COM | 2020 |
| 2020-03-03 | GENZYME CORPORATION | $150 | Research payment | Cash or cash equivalent | Pompe LSD Data Registry | 2020 | |
| 2020-03-02 | Boston Scientific Corporation | $3,058 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | ASAP TOO | 2020 |
| 2020-03-02 | FUJIFILM SonoSite, Inc. | $288 | Education | In-kind items and services | Edge/Edge II Ultrasound System Device, Medical Device | 2020 | |
| 2020-03-02 | Artivion, Inc. | $225 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | ON-X Prosthetic Heart Valve-Anatomic Suture Ring Postmarket Registry | 2020 |
| 2020-02-26 | EMD Millipore Corporation | $254 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $199 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $173 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $156 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $155 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $146 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $140 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $132 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-26 | EMD Millipore Corporation | $63 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2020 | |
| 2020-02-24 | SK Life Science, Inc. | $5,460 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C025 | 2020 |
| 2020-02-24 | Kowa Research Institute, Inc. | $3,861 | Research payment | Cash or cash equivalent | Drug | K-877-302 | 2020 |
| 2020-02-24 | SK Life Science, Inc. | $1,200 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | YKP3089C025 | 2020 |
| 2020-02-18 | SK Life Science, Inc. | $2,720 | Research payment | Cash or cash equivalent | Cenobamate Drug, Neurology | An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects with Partial O | 2020 |
| 2020-02-16 | Olympus America Inc. | $115 | Education | In-kind items and services | UGN Laser Accessories Device, Urology/Gynecology | 2020 | |
| 2020-02-14 | Amgen Inc. | $121 | Research payment | In-kind items and services | GALACTIC - HF | 2020 | |
| 2020-02-13 | Cardiovascular Systems Inc. | $5,437 | Research payment | Cash or cash equivalent | Coronary Orbital Atherectomy System Device, Atherectomy Device | ECLIPSE | 2020 |
| 2020-02-13 | CSL Behring | $801 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 | |
| 2020-02-12 | Artivion, Inc. | $3,360 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | ON-X Prosthetic Heart Valve-Anatomic Suture Ring Postmarket Registry | 2020 |
| 2020-02-10 | Eli Lilly and Company | $9,906 | Research payment | Cash or cash equivalent | EFFECT OF LY3154207 ON COGNITION IN MILD TO MODERATE PARKINSONS DISEASE DEMENTIA PDD - THE PRESENCE STUDY | 2020 | |
| 2020-02-10 | Genentech, Inc. | $5,399 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2020 |
| 2020-02-10 | Artivion, Inc. | $1,473 | Research payment | Cash or cash equivalent | On-X Device, Cardiology and Vascular Diseases | ON-X Prosthetic Heart Valve-Anatomic Suture Ring Postmarket Registry | 2020 |
The latest 200 records of 234.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Portland, ME, county Cumberland County, ME, state Maine; placed by its city name.
| Measure | Place (city or town) Portland, ME | County Cumberland County, ME | State Maine |
|---|---|---|---|
| Population B01003 | 68,854 | 308,827 | 1,387,817 |
| Population, 2020 census P1 | 68,408 | 303,069 | 1,362,359 |
| Median age B01002 | 37.8 | 42.2 | 44.8 |
| Under 18 B01001 | 15.4% | 18.0% | 18.1% |
| 65 and over B01001 | 16.9% | 20.4% | 22.4% |
| Households B11001 | 32,965 | 132,168 | 597,159 |
| Foreign born B05002 | 11.8% | 6.7% | 4.1% |
| Median household income B19013 | $79,540 | $95,677 | $74,733 |
| Median family income B19113 | $118,777 | $124,273 | $96,912 |
| Per capita income B19301 | $52,781 | $55,739 | $43,742 |
| Poverty rate B17001 | 11.2% | 7.3% | 10.7% |
| Unemployment rate B23025 | 4.2% | 3.1% | 3.8% |
| Civilian labor force B23025 | 42,094 | 175,357 | 719,683 |
| Mean commute (minutes) B08013 | 19.4 | 23.2 | 24.6 |
| Bachelor's degree or higher B15003 | 59.7% | 53.0% | 36.2% |
| Housing units B25001 | 36,559 | 153,286 | 751,876 |
| Owner-occupied B25003 | 46.9% | 69.8% | 74.3% |
| Renters B25003 | 53.1% | 30.2% | 25.7% |
| Median home value B25077 | $489,600 | $451,200 | $296,600 |
| Median gross rent B25064 | $1,577 | $1,589 | $1,139 |
| White, not Hispanic B03002 | 77.5% | 85.6% | 89.9% |
| Black B03002 | 9.1% | 3.4% | 1.8% |
| Hispanic or Latino B03002 | 3.1% | 2.8% | 2.2% |
| Asian B03002 | 3.9% | 2.2% | 1.1% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Portland, ME.
Comments